USE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR IS ASSOCIATED WITH LOW RISK OF HEPATIC DECOMPENSATIONS BUT IS NOT AFFECTING DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN TYPE II DIABETES PATIENTS.

被引:0
|
作者
Kim, Heaeun [1 ]
Kim, Jin-Wook [1 ]
Park, Jaewon [1 ]
Jang, Sangmi [2 ]
Jeong, Chan Young [1 ]
Choi, Gwang Hyeon [1 ]
Jang, Eun Sun [1 ]
Jeong, Sook-Hyang [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
1895
引用
收藏
页码:1127A / 1128A
页数:2
相关论文
共 50 条
  • [31] Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations
    Khoo, Chin Meng
    Deerochanawong, Chaicharn
    Chan, Siew Pheng
    Matawaran, Bien
    Sheu, Wayne Huey-Herng
    Chan, Juliana
    Mithal, Ambrish
    Luk, Andrea
    Suastika, Ketut
    Yoon, Kun-Ho
    Ji, Linong
    Man, Nguyen Huu
    Pollock, Carol
    DIABETES OBESITY & METABOLISM, 2021, 23 (02): : 299 - 317
  • [32] Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
    Laffel, L. M. B.
    Tamborlane, W. V.
    Yver, A.
    Simons, G.
    Wu, J.
    Nock, V.
    Hobson, D.
    Hughan, K. S.
    Kaspers, S.
    Marquard, J.
    DIABETIC MEDICINE, 2018, 35 (08) : 1096 - 1104
  • [33] Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes
    Sato, T.
    Miki, T.
    Ohnishi, H.
    Yamashita, T.
    Takada, A.
    Yano, T.
    Tanno, M.
    Tsuchida, A.
    Miura, T.
    DIABETIC MEDICINE, 2017, 34 (10) : 1367 - 1371
  • [34] Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
    Stougaard, Elisabeth B.
    Rossing, Peter
    Vistisen, Dorte
    Banks, Phillip
    Girard, Manon
    Davies, Michael J.
    Persson, Frederik
    DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1874 - 1882
  • [35] Changes in serum potassium in people with type 2 diabetes taking sodium-glucose co-transporter-2 inhibitors
    Eagan, Kellye
    Bolch, Charlotte
    Van Dril, Elizabeth
    Schumacher, Christie
    PHARMACOTHERAPY, 2025,
  • [36] The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study
    Iordan, Liana
    Lazar, Sandra
    Timar, Romulus
    Popescu, Simona
    Sorescu, Teodora
    Albai, Oana
    Braha, Adina
    Timar, Bogdan
    Gaita, Laura
    MEDICINA-LITHUANIA, 2025, 61 (02):
  • [37] Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk
    Gangat, Naseema
    Karrar, Omer
    Abdelmagid, Maymona
    Iftikhar, Moazah
    Reichard, Kaaren K.
    Szuber, Natasha
    Tefferi, Ayalew
    BLOOD, 2023, 142
  • [38] Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers
    Yang, Jeff Y.
    Wang, Tiansheng
    Pate, Virginia
    Gower, Emily W.
    Crowley, Matthew J.
    Buse, John B.
    Sturmer, Til
    DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1223 - 1236
  • [39] SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ASSOCIATED WITH LOWER RISK OF HEPATOCELLULAR CARCINOMA AND HEPATIC DECOMPENSATION IN TYPE 2 DIABETES MELLITUS
    Cheung, Ka Shing
    Mao, Xianhua
    Tan, Jing Tong
    Cheng, Ho Ming
    Yuen, Man-Fung
    Seto, Wai-Kay
    GASTROENTEROLOGY, 2024, 166 (05) : S1563 - S1563
  • [40] Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
    Alkagiet, Stelina
    Tziomalos, Konstantinos
    WORLD JOURNAL OF DIABETES, 2020, 11 (05) : 150 - 154